SBIR/STTR Research Award
SCREENING FOR TOLEROGENIC ADJUVANTS TO ENHANCE ANTIGEN SPECIFIC IMMUNOTHERAPY FOR CELIAC DISEASE.
Award amount
$599,945Program and phase
SBIR · Phase IAward year
2023Award details
- Awarding agency
- Department of Health and Human Services
- Branch
- National Institutes of Health
- Recipient company
- Qrono, Inc.
- Proposal award date
- Not reported
- Contract end date
- Not reported
- UEI
- S8NSYCMSNF79
- Solicitation number
- PHS-2023-1
- Topic code
- 116
Research abstract
Celiac disease (CD) is a human chronic autoimmune disorder of the small intestine driven by adaptive immune responses to gluten peptides in wheat, barley, and rye. The contractor is targeting dendritic cells and macrophages to discovery new tolerogenic adjuvants which when paired with gluten antigens, may enable the first clinically viable immunotherapy for CD patients.
Technology keywords
Not reported
Other awards by this recipient
Verified by the same UEI. These are other public SBIR/STTR award pages, not a merged company record.
- Restoring Tolerance in Inflammatory Bowel Disease with an Oral AMPK agonist Nanomedicine that Targets Antigen Presenting Cells.
- Restoring Tolerance with an Oral AMPK Agonist Nanomedicine Targeting Intestinal Dendritic Cells as a Preventative Therapy for Type 1 Diabetes
- APC SPECIFIC MTOP INHIBITION POTENTIATES IMMUNE RESPONSE TO IIV IN ELDERLY RECIPIENTS.
- IGF OT IGF FAILED TUBULIN INHIBITOR REFORMULATED AS LOCALIZED ADJUVANT THERAPY FOR HEAD AND NECK CANCER
- Computationally designed adjuvant platform enhancing dengue vaccine immunogenicity
Awards with the same topic code
Verified by an exact topic code match. This is not a text-similarity match.
Research funding history
10 SBIR/STTR records share this UEI (2013–2024). Reported award amounts total $5,289,085. Reported amounts are not federal obligations.
Phases: Phase I, Phase II
Agencies: Department of Health and Human Services, Department of Defense